Related Experiment Video
Updated: Mar 9, 2026

Isolation, Enrichment, and Maintenance of Medulloblastoma Stem Cells
Published on: September 1, 2010
Reprogramming Medulloblastoma-Propagating Cells by a Combined Antagonism of Sonic Hedgehog and CXCR4
Stacey A Ward1, Nicole M Warrington1, Sara Taylor1
1Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri.
Abstract:
The CXCR4 chemokine and Sonic Hedgehog (SHH) morphogen pathways are well-validated therapeutic targets in cancer, including medulloblastoma. However, single-agent treatments with SHH or CXCR4 antagonists have not proven efficacious in clinical trials to date. Here, we discovered that dual inhibition of the SHH and CXCR4 pathways in a murine model of SHH-subtype medulloblastoma exerts potent antitumor effects. This therapeutic synergy resulted in the suppression of tumor-propagating cell function and correlated with increased histone H3 lysine 27 trimethylation within the promoters of stem cell genes, resulting in their decreased expression. These results demonstrate that CXCR4 contributes to the epigenetic regulation of a tumor-propagating cell phenotype. Moreover, they provide a mechanistic rationale to evaluate the combination of SHH and CXCR4 inhibitors in clinical trials for the treatment of medulloblastoma, as well as other cancers driven by SHH that coexpress high levels of CXCR4. Cancer Res; 77(6); 1416-26. ©2016 AACR.
Insights
Dual inhibition of Sonic Hedgehog (SHH) and CXCR4 pathways shows potent antitumor effects in medulloblastoma. This combination therapy suppresses tumor-propagating cells by altering gene expression, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Therapeutics
Background:
- Sonic Hedgehog (SHH) and CXCR4 pathways are validated therapeutic targets in medulloblastoma.
- Previous clinical trials of single-agent SHH or CXCR4 inhibitors have shown limited efficacy.
Purpose of the Study:
- To investigate the efficacy of dual inhibition of SHH and CXCR4 pathways in a murine model of SHH-subtype medulloblastoma.
- To elucidate the underlying mechanisms of synergistic antitumor effects.
Main Methods:
- Utilized a murine model of SHH-subtype medulloblastoma.
- Administered dual inhibitors targeting both SHH and CXCR4 pathways.
- Assessed tumor-propagating cell function and epigenetic modifications (histone H3 trimethylation).
Main Results:
- Dual inhibition of SHH and CXCR4 pathways demonstrated potent antitumor effects.
- Therapeutic synergy suppressed tumor-propagating cell function.
- Observed increased histone H3 lysine 27 trimethylation in stem cell gene promoters, leading to decreased gene expression.
Conclusions:
- CXCR4 plays a role in the epigenetic regulation of tumor-propagating cell phenotype.
- Combination therapy of SHH and CXCR4 inhibitors provides a mechanistic rationale for clinical trials in medulloblastoma.
- This approach may also benefit other SHH-driven cancers with high CXCR4 coexpression.
Related Concept Videos
Hedgehog Signaling Pathway
Somatic to iPS Cell Reprogramming
Methods of Nuclear Reprogramming

